Skip Navigation



Annals of Oncology Advance Access published online on July 12, 2005
Annals of Oncology, doi:10.1093/annonc/mdi316
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/10/1646    most recent
mdi316v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Westra, J. L.
Right arrow Articles by Plukker, J. Th. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westra, J. L.
Right arrow Articles by Plukker, J. Th. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received March 18, 2005
Revised June 6, 2005
Accepted June 7, 2005

Original article

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients

J. L. Westra 1, H. Hollema 2, M. Schaapveld 3, I. Platteel 2, K. A. Oien 4, W. N. Keith 4, R. Mauritz 5, G. J. Peters 5, C. H. C. M. Buys 1, R. M. W. Hofstra 1, and J. Th. M. Plukker 6*

1 Department of Medical Genetics, University Medical Center Groningen, Groningen, The Netherlands
2 Department of Pathology, University Medical Center Groningen, Groningen, The Netherlands
3 Comprehensive Cancer Centre North Netherlands, Groningen, The Netherlands
4 Department of Medical Oncology, University of Glasgow, Cancer Research UK Beatson Laboratories, Glasgow, UK
5 Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands
6 Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands

* To whom correspondence should be addressed.
J. Th. M. Plukker, E-mail: j.th.plukker{at}chir.umcg.nl


  Abstract

Background: The predictive value of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression on long-term survival by influencing 5-fluorouracil (5-FU) effect were determined in primary tumours and node metastases of stage III colon cancer patients treated adjuvantly with 5-FU regimens (n = 391). The effect of TP53 mutation status, which is thought to be functionally linked to TS inhibition, was also examined.

Patients and methods: TS and DPD protein expression was determined by immunohistochemical analysis using tissue microarrays of these colon tumours. Two hundred and twenty tumours had already been screened in a previous study for TP53 mutations.

Results: Low TS protein levels in primary stage III colon tumours appeared to be associated with mucinous histology and low DPD protein levels with young age at time of randomisation. Concordance between TS and DPD expression in primary and metastatic tumours was low. No associations were found between disease-free survival (DFS) and TS or DPD protein levels. When stratified by TP53 mutation status DFS did not differ with TS expression.

Conclusions: Expression of TS and DPD proteins is not predictive for survival in patients with stage III colon cancer treated adjuvantly with 5-FU regimens. TS protein levels did not alter the effect of TP53 mutation status.

Keywords: colon cancer; dihydropyrimidine dehydrogenase; prediction 5-fluorouracil regimen; thymidylate synthase; TP53.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Rikhof, J. van Doorn, A. J. H. Suurmeijer, M. W. Rautenberg, P. J. T. A. Groenen, M. A. J. Verdijk, P. L. Jager, S. de Jong, J. A. Gietema, and W. T. A. van der Graaf
Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour
Ann. Onc., September 1, 2009; 20(9): 1582 - 1588.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Soong, N. Shah, M. Salto-Tellez, B. C. Tai, R. A. Soo, H. C. Han, S. S. Ng, W. L. Tan, N. Zeps, D. Joseph, et al.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy
Ann. Onc., May 1, 2008; 19(5): 915 - 919.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Popat, Z Chen, D Zhao, H Pan, N Hearle, I Chandler, Y Shao, W Aherne, and R. Houlston
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
Ann. Onc., December 1, 2006; 17(12): 1810 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. van Geelen, J. L. Westra, E. G. de Vries, W. Boersma-van Ek, N. Zwart, H. Hollema, H. M. Boezen, N. H. Mulder, J. T. Plukker, S. de Jong, et al.
Prognostic Significance of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients
J. Clin. Oncol., November 1, 2006; 24(31): 4998 - 5004.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Rubio-Viqueira, A. Jimeno, G. Cusatis, X. Zhang, C. Iacobuzio-Donahue, C. Karikari, C. Shi, K. Danenberg, P. V. Danenberg, H. Kuramochi, et al.
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Clin. Cancer Res., August 1, 2006; 12(15): 4652 - 4661.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.